Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Brett Newswanger, Steven Prestrelski & Anthony D. Andre. (2019) Human factors studies of a prefilled syringe with stable liquid glucagon in a simulated severe hypoglycemia rescue situation. Expert Opinion on Drug Delivery 16:9, pages 1015-1025.
Read now
Read now
Irl B. Hirsch. (2017) Professional flash continuous glucose monitoring as a supplement to A1C in primary care. Postgraduate Medicine 129:8, pages 781-790.
Read now
Read now
Nicki Hoskins, Christian Klyver Tikkanen & Ulrik Pedersen-Bjergaard. (2017) The economic impact of insulin-related hypoglycemia in Denmark: an analysis using the Local Impact of Hypoglycemia Tool. Journal of Medical Economics 20:4, pages 363-370.
Read now
Read now
Lena Landstedt-Hallin, Jens Gundgaard, Åsa Ericsson & Susanne Ellfors-Zetterlund. (2017) Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data. Current Medical Research and Opinion 33:4, pages 647-655.
Read now
Read now
Charles Shaefer, Debbie Hinnen & Christopher Sadler. (2016) Hypoglycemia and diabetes: increased need for awareness. Current Medical Research and Opinion 32:9, pages 1479-1486.
Read now
Read now
Frank Lavernia, Pamela Kushner, Dace Trence, Donna Rice, George Dailey & Louis Kuritzky. (2015) Recognizing and minimizing hypoglycemia: The need for individualized care. Postgraduate Medicine 127:8, pages 801-807.
Read now
Read now
Michał Jakubczyk, Elżbieta Rdzanek, Maciej Niewada & Marcin Czech. (2015) Economic resources consumption structure in severe hypoglycemia episodes: a systematic review and meta-analysis. Expert Review of Pharmacoeconomics & Outcomes Research 15:5, pages 813-822.
Read now
Read now
Gemma Sutton, Joan Minguet, Carmen Ferrero & Peter Bramlage. (2014) U300, a novel long-acting insulin formulation. Expert Opinion on Biological Therapy 14:12, pages 1849-1860.
Read now
Read now
Gregory Fulcher, Joelle Singer, Rutila Castañeda, Fadlo Fraige Filho, Laura Maffei, Jacques Snyman & Meryl Brod. (2014) The psychosocial and financial impact of non-severe hypoglycemic events on people with diabetes: two international surveys. Journal of Medical Economics 17:10, pages 751-761.
Read now
Read now
Stanley Schwartz. (2014) Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes. Postgraduate Medicine 126:3, pages 66-84.
Read now
Read now
Meryl Brod, Michael Wolden, Danielle Groleau & Donald M. Bushnell. (2014) Understanding the economic, daily functioning, and diabetes management burden of non-severe nocturnal hypoglycemic events in Canada: differences between type 1 and type 2. Journal of Medical Economics 17:1, pages 11-20.
Read now
Read now
Articles from other publishers (28)
Allyson S. Hughes, Katherine S. Chapman, Huyen Nguyen, Jingwen Liu, Jeoffrey Bispham, Melissa Winget, Stuart A. Weinzimer & Wendy A. Wolf. (2023) Severe Hypoglycemia and the Use of Glucagon Rescue Agents: An Observational Survey in Adults With Type 1 Diabetes. Clinical Diabetes 41:3, pages 399-410.
Crossref
Crossref
James R. GavinClifford J. Bailey. (2021) Real-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen. Diabetes Technology & Therapeutics 23:S3, pages S-19-S-27.
Crossref
Crossref
Davida F. KrugerJohn E. Anderson. (2021) Continuous Glucose Monitoring (CGM) Is a Tool, Not a Reward: Unjustified Insurance Coverage Criteria Limit Access to CGM. Diabetes Technology & Therapeutics 23:S3, pages S-45-S-55.
Crossref
Crossref
Hannah Chatwin, Melanie Broadley, Jane Speight, Anna Cantrell, Anthea Sutton, Simon Heller, Bastiaan de Galan, Christel Hendrieckx & Frans Pouwer. (2021) The impact of hypoglycaemia on quality of life outcomes among adults with type 1 diabetes: A systematic review. Diabetes Research and Clinical Practice 174, pages 108752.
Crossref
Crossref
Samer Muthana Sarsam, Hosam Al-Samarraie & Ahmed Al-Sadi. (2020) Disease discovery-based emotion lexicon: a heuristic approach to characterise sicknesses in microblogs. Network Modeling Analysis in Health Informatics and Bioinformatics 9:1.
Crossref
Crossref
Sarang Jeong, Jung Min Cho, Young-In Kwon, Seong-Chul Kim, Dong Yeob Shin & Jong Ho Lee. (2019) Chitosan oligosaccharide (GO2KA1) improves postprandial glycemic response in subjects with impaired glucose tolerance and impaired fasting glucose and in healthy subjects: a crossover, randomized controlled trial. Nutrition & Diabetes 9:1.
Crossref
Crossref
Virginia ValentineBrett NewswangerSteve PrestrelskiAnthony D. AndreMark Garibaldi. (2019) Human Factors Usability and Validation Studies of a Glucagon Autoinjector in a Simulated Severe Hypoglycemia Rescue Situation. Diabetes Technology & Therapeutics 21:9, pages 522-530.
Crossref
Crossref
Domingo Orozco-Beltrán, Sara Artola, Margarida Jansà, Martin Lopez de la Torre-Casares & Eva Fuster. (2018) Impact of hypoglycemic episodes on health-related quality of life of type-2 diabetes mellitus patients: development and validation of a specific QoLHYPO© questionnaire. Health and Quality of Life Outcomes 16:1.
Crossref
Crossref
David C. Tabano, Melissa L. Anderson, Debra P. Ritzwoller, Arne Beck, Nikki Carroll, Paul A. Fishman & David C. Grossman. (2018) Estimating the Impact of Diabetes Mellitus on Worker Productivity Using Self-Report, Electronic Health Record and Human Resource Data. Journal of Occupational & Environmental Medicine 60:11, pages e569-e574.
Crossref
Crossref
Marc Evans, Roopa Mehta, Jens Gundgaard & Barrie Chubb. (2018) Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting. Diabetes Therapy 9:5, pages 1919-1930.
Crossref
Crossref
Rozalina G. McCoy, Jeph Herrin, Kasia J. Lipska & Nilay D. Shah. (2018) Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among U.S. adults with diabetes. Journal of Diabetes and its Complications 32:7, pages 693-701.
Crossref
Crossref
Irl B. Hirsch & Carol A. Verderese. (2017) Professional Flash Continuous Glucose Monitoring with Ambulatory Glucose Profile Reporting to Supplement A1c: Rationale and Practical Implementation. Endocrine Practice 23:11, pages 1333-1344.
Crossref
Crossref
B. Detournay, S. Halimi, E. Torreton & P. Levy. (2017) Coût des hospitalisations pour hypoglycémie en France chez les patients diabétiques de type 2 : étude fondée sur le PMSI et la base EGB de la CNAMTS. Médecine des Maladies Métaboliques 11, pages IIS16-IIS19.
Crossref
Crossref
Kamuran Turksoy, Nicole Frantz, Laurie Quinn, Magdalena Dumin, Jennifer Kilkus, Brooks Hibner, Ali Cinar & Elizabeth Littlejohn. (2017) Automated Insulin Delivery—The Light at the End of the Tunnel. The Journal of Pediatrics 186, pages 17-28.e9.
Crossref
Crossref
C.B. Giorda, M.C. Rossi, O. Ozzello, S. Gentile, A. Aglialoro, A. Chiambretti, F. Baccetti, F.M. Gentile, F. Romeo, G. Lucisano, A. Nicolucci, R. Fornengo, A. Alessiato, A. Ozzello, L. Sciangula, N. Musacchio, G. Marelli, A. Corsi, F. Baccetti, V. Paciotti, R. Iannarelli, D. Antenucci, F. Chiaramonte, S. Leotta, S. Gentile, V. Armentano, F.M. Gentile, F. Mastinu & D. Cucinotta. (2017) Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study. Nutrition, Metabolism and Cardiovascular Diseases 27:3, pages 209-216.
Crossref
Crossref
Helena W. Rodbard, Anne L. Peters, April Slee, Anjun Cao, Shana B. Traina & Maria Alba. (2017) The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes. Diabetes Care 40:2, pages 171-180.
Crossref
Crossref
Meryl Brod, Gagik Galstyan, Ambika Gopalakrishnan Unnikrishnan, Ilana Harman-Boehm, Vinay Prusty, Fernando Lavalle, Margaret McGill, Angela Murphy & Felix Puchulu. (2016) Self-Treated Hypoglycemia in Type 2 Diabetes Mellitus: Results from the Second Wave of an International Cross-Sectional Survey. Diabetes Therapy 7:2, pages 279-293.
Crossref
Crossref
Sang Youl Rhee, Soo Min Hong, Suk Chon, Kyu Jeung Ahn, Sung Hoon Kim, Sei Hyun Baik, Yong Soo Park, Moon Suk Nam, Kwan Woo Lee, Jeong-Taek Woo & Young Seol Kim. (2016) Hypoglycemia and Medical Expenses in Patients with Type 2 Diabetes Mellitus: An Analysis Based on the Korea National Diabetes Program Cohort. PLOS ONE 11:2, pages e0148630.
Crossref
Crossref
Winston Crasto, Janet Jarvis & Melanie J. DaviesWinston Crasto, Janet Jarvis & Melanie J. Davies. 2016. Handbook of Insulin Therapies. Handbook of Insulin Therapies
169
209
.
Marcin Czech, Elżbieta Rdzanek, Justyna Pawęska, Olga Adamowicz-Sidor, Maciej Niewada & Michał Jakubczyk. (2015) Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis. BMC Endocrine Disorders 15:1.
Crossref
Crossref
Naoki Sakane, Kazuhiko Kotani, Kokoro Tsuzaki, Masami Nishi, Kaoru Takahashi, Takashi Murata, Kazunori Yamada, Kentaro Okazaki, Katsuyuki Yanagisawa, Kenichi Yamada, Nobuichi Kuribayashi, Yasuo Totsuka, Toru Hiyoshi, Motoji Naka, Masatake Sugimoto, Yuji Aoki, Masako Waki, Miyuki Furuya, Haruko Kitaoka, Mariko Oishi, Ikki Shimizu, Hiroaki Miyaoka, Akira Okada & Toshikazu Yamamoto. (2015) Fear of hypoglycemia and its determinants in insulin‐treated patients with type 2 diabetes mellitus. Journal of Diabetes Investigation 6:5, pages 567-570.
Crossref
Crossref
Richard M. Bergenstal. (2015) Glycemic Variability and Diabetes Complications: Does It Matter? Simply Put, There Are Better Glycemic Markers!. Diabetes Care 38:8, pages 1615-1621.
Crossref
Crossref
Arthur T. Sands, Brian P. Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W. Bode, Satish K. Garg, John B. Buse, Phillip Banks, Rubina Heptulla, Marc Rendell, William T. Cefalu & Paul Strumph. (2015) Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care 38:7, pages 1181-1188.
Crossref
Crossref
S. Roze, R. Saunders, A.-S. Brandt, S. de Portu, N. L. Papo & J. Jendle. (2015) Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes. Diabetic Medicine 32:5, pages 618-626.
Crossref
Crossref
David M. Maahs, Stephen R. Daniels, Sarah D. de Ferranti, Helén L. Dichek, Joseph Flynn, Benjamin I. Goldstein, Aaron S. Kelly, Kristen J. Nadeau, Pamela Martyn-Nemeth, Stavroula K. Osganian, Laurie Quinn, Amy S. Shah & Elaine Urbina. (2014) Cardiovascular Disease Risk Factors in Youth With Diabetes Mellitus. Circulation 130:17, pages 1532-1558.
Crossref
Crossref
Steven Edelman & Jeremy Pettus. (2014) Challenges Associated with Insulin Therapy in Type 2 Diabetes Mellitus. The American Journal of Medicine 127:10, pages S11-S16.
Crossref
Crossref
Robert R. Henry, Julio Rosenstock, Douglas Logan, Thomas Alessi, Kenneth Luskey & Michelle A. Baron. (2014) Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. Journal of Diabetes and its Complications 28:3, pages 393-398.
Crossref
Crossref
Hee Jun Kim, Hyeon Yeong Ahn, Jung Hyun Kwak, Dong Yeob Shin, Young-In Kwon, Chen-Gum Oh & Jong Ho Lee. (2014) The effects of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes. Food Funct. 5:10, pages 2662-2669.
Crossref
Crossref